Inogen (INGN)
(Delayed Data from NSDQ)
$8.69 USD
-0.04 (-0.46%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $8.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.69 USD
-0.04 (-0.46%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $8.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.
Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children
by Zacks Equity Research
Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.
Integra LifeSciences Codman Arm Strong, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
Inogen's Solid Europe Business Shapes Q2, Prospects Bright
by Zacks Equity Research
Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.
Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes
by Zacks Equity Research
Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.
Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid
by Zacks Equity Research
Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.
Boston Scientific to Expand Within PI Via VENITI Buyout
by Zacks Equity Research
Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.
Becton, Dickinson Global Foothold Strong, Recalls Rampant
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.
Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now
by Zacks Equity Research
DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Ecolab (ECL) is likely to gain from a robust product portfolio, new product launches and expanding customer base.
Varian Acquires humediQ, Boosts Motion Management Portfolio
by Zacks Equity Research
Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.
Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance
by Zacks Equity Research
Inogen (INGN) puts up solid segmental show in Q2; international sales surge.
Inogen (INGN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 47.73% and 19.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
RTIX or INGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RTIX vs. INGN: Which Stock Is the Better Value Option?
LivaNova (LIVN) Soars: Stock Adds 10.4% in Session
by Zacks Equity Research
LivaNova (LIVN) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
Integer Holdings (ITGR) Catches Eye: Stock Jumps 7.5%
by Zacks Equity Research
Integer Holdings (ITGR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Inogen's (INGN) solid product portfolio is a key catalyst. Also, the company benefits from strong focus in Europe.
Zacks.com featured highlights include: Johnson Outdoors, Home, Inogen, Blucora and Weight Watchers
by Zacks Equity Research
Zacks.com featured highlights include: Johnson Outdoors, Home, Inogen, Blucora and Weight Watchers
5 Profitable Stocks to Scoop Up Spectacular Returns
by Zacks Equity Research
Profitability analysis is one of the best tools to evaluate the future movement of a stock.
Stryker or Baxter: Which is a Better Pick for Your Portfolio?
by Zacks Equity Research
Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for XHE
Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View
by Zacks Equity Research
Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.
What's in the Cards for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.
Why Is Inogen (INGN) Down 7% Since its Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.